Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Severe GI Toxicities Remain a Significant Source of Clinical Meaningful Morbidity Especially in Older Patients Receiving Autologous Transplant for Lymphoma

Geoffrey Shouse, Annabel Kate Frank, Sanjay K. Aggarwal, Edward Kavalerchik, John K Frazer, Paul Finnegan, Bita Fakhri

Blood (2021) 138 (Supplement 1): 4899.

https://doi.org/10.1182/blood-2021-151018

Published: 2021

Journal Articles

Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Michael Scordo, MD, Lihua E Budde, MD PhD, Mehrdad Abedi, MD, Carolyn Mulroney, MD, Bita Fakhri, MDMPH, Attaphol Pawarode, MDPhD, Bhagirathbhai Dholaria, MBBS, Edward Kavalerchik, MD, Sanjay K. Aggarwal, MD, Muzaffar H. Qazilbash, MD, Paul Finnegan, MD, Sergio A. Giralt, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137257

Published: 2020

Journal Articles

Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma

Ravi Vij, MD, Michael Wang, MD, Sundar Jagannath, MD, Ruben Niesvizky, MD, Andrzej J. Jakubowiak, MD, PhD, Edward Kavalerchik, MD, Mei Huang, MS, David S. Siegel, MD, PhD

Blood (2013) 122 (21): 1965.

https://doi.org/10.1182/blood.V122.21.1965.1965

Published: 2013

Journal Articles

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

Michael Wang, Tom Martin, William Bensinger, Melissa Alsina, David S. Siegel, Edward Kavalerchik, Mei Huang, Robert Z. Orlowski, Ruben Niesvizky

Blood (2013) 122 (18): 3122–3128.

https://doi.org/10.1182/blood-2013-07-511170

Published: 2013

Includes: Supplemental data

Journal Articles

A Novel Mouse Xenograft Model for Generation of JAK2 V617F Driven Leukemic Stem Cells From Human Embryonic Stem Cells.

Edward Kavalerchik, MD, Charlene Barroga, PhD, Larissa Balaian, PhD, Jennifer M. Black, MD, Catriona H.M. Jamieson, MD, PhD

Blood (2009) 114 (22): 1433.

https://doi.org/10.1182/blood.V114.22.1433.1433

Published: 2009

Journal Articles

Missplicing of Glycogen Synthase Kinase 3β: A Potential Mechanism of Blast Crisis Chronic Myeloid Leukemia Stem Cell Generation.

Annelie Abrahamsson, MS, Ifat Geron, MS, Jason Gotlib, MD MS, Kim-Hien Dao, DO PhD, Francis Giles, MD, Isabel Newton, MD PhD, Edward Kavalerchik, MD, Jeffrey Durocher, PhD, Remi Creusot, PhD, Mobin Karimi, PhD, Carol Jones, PhD, James Zehnder, PhD, Armand Keating, MD, Robert Negrin, MD, Irving L. Weissman, MD, Catriona H.M. Jamieson, MD PhD

Blood (2007) 110 (11): 775.

https://doi.org/10.1182/blood.V110.11.775.775

Published: 2007

Journal Articles

Inhibition of Chronic Myelogenous Leukemia Stem Cells with Novel Wnt Antagonists.

Edward Kavalerchik, MD, Jason Gotlib, MD MS, Ifat Geron, MS, Annelie Abrahamsson, MS, Wolfgang Wrasidlo, PhD, Daniel Goff, BS, Desheng Lu, PhD, Ted Molinski, PhD, Francis Giles, MD, Irving Weissman, MD, Dennis Carson, MD, Catriona Jamieson, MD PhD

Blood (2006) 108 (11): 238.

https://doi.org/10.1182/blood.V108.11.238.238

Published: 2006

Journal Articles

Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.

Ifat Geron, MS, Charlene Barroga, PhD, Jason Gotlib, MD MS, Edward Kavalerchik, MD, Annelie Abrahamsson, MS, Daniel Goff, BS, Nicholas Cacalano, PhD, John Hood, PhD, Richard Soll, MD, Glenn Noronha, PhD, Ayalew Tefferi, MD, Irving L. Weissman, MD, Kenneth Kaushansky, MD PhD, Catriona Jamieson, MD, PhD

Blood (2006) 108 (11): 3616.

https://doi.org/10.1182/blood.V108.11.3616.3616

Published: 2006

Journal Articles

Aberrant Regulation of Wnt/Beta-Catenin Pathway Mediators in Chronic Myelogenous Leukemia Stem Cells.

Annelie Abrahamsson, MS, Ifat Geron, MS, Jason Gotlib, MD MS, Jeffrey Durocher, PhD, Remi Creusot, PhD, Edward Kavalerchik, MD, Daniel Goff, BS, C.G. Fathman, MD, Stanley L. Lilleberg, PhD, Francis Giles, MD, Irving Weissman, MD, Catriona Jamieson, MD, PhD

Blood (2006) 108 (11): 2135.

https://doi.org/10.1182/blood.V108.11.2135.2135

Published: 2006

NARROW

Severe GI Toxicities Remain a Significant Source of Clinical Meaningful Morbidity Especially in Older Patients Receiving Autologous Transplant for Lymphoma

Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

A Novel Mouse Xenograft Model for Generation of JAK2 V617F Driven Leukemic Stem Cells From Human Embryonic Stem Cells.

Missplicing of Glycogen Synthase Kinase 3β: A Potential Mechanism of Blast Crisis Chronic Myeloid Leukemia Stem Cell Generation.

Inhibition of Chronic Myelogenous Leukemia Stem Cells with Novel Wnt Antagonists.

Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.

Aberrant Regulation of Wnt/Beta-Catenin Pathway Mediators in Chronic Myelogenous Leukemia Stem Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only